HALDOL LA INJ 100MG/ML DIN 00599093
Health Canada record
| Active ingredient(s) | HALOPERIDOL DECANOATE 100 MG |
|---|---|
| Dosage form | Liquid |
| Route | Intramuscular |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N05AD01 HALOPERIDOL |
| Original market date | 31-Dec-1983 |
| Current status date | 04-Aug-2006 |
| Source | Health Canada DPD |
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing HALOPERIDOL DECANOATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00599085 | HALDOL LA INJ 50MG/ML | JANSSEN INC | Liquid | HALOPERIDOL DECANOATE 50 MG | Cancelled Post Market |
| 02211149 | RHO-HALOPERIDOL DECANOATE INJ.-IM 100MG/ML | RHODIAPHARM INC | Solution | HALOPERIDOL DECANOATE 100 MG | Cancelled Post Market |
| 02211130 | RHO-HALOPERIDOL DECANOATE INJ.-IM 50MG/ML | RHODIAPHARM INC | Solution | HALOPERIDOL DECANOATE 50 MG | Cancelled Post Market |
International API supply for HALOPERIDOL DECANOATE
3 valid EDQM Certificates of Suitability from 3 holders. 6 active FDA Drug Master Files.
Request a quote for HALDOL LA INJ 100MG/ML